Retrophin, which is developing Syntocinon intranasal oxytocin, has named Stephen Aselage as President and Chief Operations Officer and Alvin Shih as Executive VP of Research and Development. Aselage, who has stepped down as CEO, was Executive VP and Chief Business Officer at BioMarin Pharmaceutical before joining Retrophin in 2012, and Shih is currently COO of Pfizer’s Rare Disease Research Unit.
Retrophin Founder and CEO Martin Shkreli commented, “Steve has been a trusted advisor to Retrophin since our formation, having served as a key member of our board of directors. I have no doubt that the expertise Steve has accumulated during his more than 30-year career in the global pharmaceutical industry will be invaluable as we continue advancing our pipeline of treatments for catastrophic diseases and expanding our commercial product portfolio through strategic transactions.”
About Shih, he said, “I am delighted to welcome Alvin to the Retrophin team in this very important leadership position. His rare disease R&D experience and business acumen will be invaluable as we continue to advance and grow our pipeline of drugs for patients suffering from serious diseases that currently have no viable treatment options.”
Read the Retrophin press release on Aselage.
Read the Retrophin press release on Shih.
